Inventiva Will Present MASH Research at Denver Congress
The company will share three scientific abstracts detailing the biological rationale for lanifibranor in Denver.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Do you trust that current pharmaceutical research is effectively leading to better treatments for chronic diseases?
Inventiva will present three scientific abstracts at AASLD The Liver Meeting 2026, which begins in Denver on November 5, 2026. The research explores the biological rationale for the pan-PPAR approach of the investigational medicine lanifibranor.
Why it matters
These presentations offer translational insights into how targeting PPAR isoforms simultaneously may address the complex drivers of MASH pathophysiology. Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial.
Preclinical and Phase 2b results demonstrated that lanifibranor improves liver sinusoidal endothelial cell alterations. The data further identified epigenetic changes across the PPAR family in patients with MASLD.
The players
Inventiva
This is a biopharmaceutical company headquartered in Daix, France, and New York City that focuses on developing treatments for liver and metabolic diseases.
AASLD
The American Association for the Study of Liver Diseases is an organization dedicated to the prevention and cure of liver diseases through research and education.
The details
The upcoming posters will describe the mechanism of lanifibranor, which activates PPAR alpha, delta, and gamma isoforms to regulate gene expression. The FDA has already granted the investigational medicine both Breakthrough Therapy and Fast Track designation.
Timeline
November 5, 2026: The meeting begins and the first abstract is presented.
November 7, 2026: The second and third abstracts are presented.
November 9, 2026: The medical meeting concludes in Denver.
Q4 2026: Expected topline results from the NATiV3 clinical trial.
The Big Picture
The presentations at AASLD correlate with progress in the NATiV3 clinical trial for MASH. These findings provide the scientific groundwork for the Phase 3 NATiV3 clinical trial currently underway.
As an investigational medicine, lanifibranor is not currently approved by any regulatory authority for public use. Patients should monitor the NATiV3 trial progress for future updates on treatment availability.
The takeaway
The research highlights the complex effort to address metabolic dysfunction-associated steatohepatitis through multi-target drug development. Investors and patients should look for topline results from the Phase 3 trial expected later in 2026.
Further reading
For more information on current developments in respiratory and metabolic conditions, visit Denver Asthma.
Live Poll
Do you trust that current pharmaceutical research is effectively leading to better treatments for chronic diseases?
